Phase II trial studies show that linifanib is useful for the treatment of patients with advanced, refractory col- orectal cancer that expresses k-Ras mutations [65]. In an open-label phase II trial linifanib showed interesting clinical activity, as monotherapy, in patients with advanced HCC [66...